The identification of a circulating serum miRNA signature may offer a noninvasive strategy to improve diagnostic discrimination between rheumatoid arthritis and psoriatic arthritis.
The identification of a circulating serum miRNA signature may offer a noninvasive strategy to improve diagnostic discrimination between rheumatoid arthritis and psoriatic arthritis.
Improved recognition and targeted assessment are essential to avoid misclassification of disease activity for patients with psoriatic arthritis and fibromyalgia.
Improved recognition and targeted assessment are essential to avoid misclassification of disease activity for patients with psoriatic arthritis and fibromyalgia.
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
In part 1 of a two-part podcast, Dr Mease reviews the findings of two clinical trials of the TYK 2 inhibitor deucravacitinib: POETYK 1 of patients without previous biologic treatment, POETYK 2, which included some patients with exposure to...
Dr Singla reviews the comparative analysis she and colleagues conducted of guidelines for the diagnosis and treatment of psoriatic arthritis and how they differ between the professional societies.
Dr Singla reviews the comparative analysis she and colleagues conducted of guidelines for the diagnosis and treatment of psoriatic arthritis and how they differ between the professional societies.
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
Dr Paudel reviews research she and colleagues conducted to validate the EULAR definition of difficult-to-treat rheumatoid arthritis, and differences among patients with difficult-to-treat RA versus those with controlled disease.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
A recent study found no significant difference in the risk of cardiovascular events among rheumatoid arthritis patients treated with Janus kinase inhibitors or biologic disease-modifying drugs.
